CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. CorMedix Inc. (NASDAQ:CRMD) stands sixth among them.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on therapies to prevent and treat life-threatening diseases, with DefenCath, an antimicrobial catheter lock for dialysis patients, as its lead commercial product.

In August 2025, CorMedix Inc. (NASDAQ:CRMD) announced the acquisition of Melinta Therapeutics, a commercial-stage company with seven marketed hospital- and clinic-focused infectious disease products, including REZZAYO™ for candidemia and invasive candidiasis. The acquisition, expected to close by September 1, will diversify CRMD’s portfolio, expand its acute hospital care presence, and enhance R&D and commercial capabilities. The combined company is projected to generate $305–$335 million in 2025 revenue, with annual synergies of $35–$45 million, and is expected to be accretive to earnings with double-digit EPS growth in 2026. This strategic move also highlights how CRMD, often categorized among overlooked stocks, is positioning itself for broader recognition in the healthcare space.

CorMedix Inc. (NASDAQ:CRMD) continues to see strong growth in DefenCath sales, supporting its market position. The corporation faces some legal challenges from shareholder lawsuits alleging misleading statements, contributing to stock volatility.

While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.